Limits...
Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Gibreel A, Bhattacharya S - Biologics (2010)

Bottom Line: Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism.Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy.However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine and Dentistry, University of Aberdeen;

ABSTRACT
Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.

No MeSH data available.


Related in: MedlinePlus

Meta-analysis of randomized trials of hMG versus rFSH for the outcome of pregnancy rate per patient in women undergoing ovulation induction for subfertility associated with polycystic ovarian syndrome. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001;2(2):CD002121.128 Copyright © Cochrane Collaboration, reproduced with permission.Abbreviations: HMG, human menopausal gonadotropin; RFSH, recombinant follicle stimulating hormone.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2819896&req=5

f2-btt-4-005: Meta-analysis of randomized trials of hMG versus rFSH for the outcome of pregnancy rate per patient in women undergoing ovulation induction for subfertility associated with polycystic ovarian syndrome. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001;2(2):CD002121.128 Copyright © Cochrane Collaboration, reproduced with permission.Abbreviations: HMG, human menopausal gonadotropin; RFSH, recombinant follicle stimulating hormone.

Mentions: The first baby born after ovulation induction by follitropin in a clomiphene resistant PCOS patient was reported in 1992.122 Randomized trials comparing follitropin alpha to other gonadotropins preparation or other ovulatory medications, in infertile women with WHO type II anovulation, have reported a live birth rate of 17% to 20%.59,123,124 The rate of successful ovulation has been reported to be between 57% and 85%.33,125–127 The pooled ovulation rate per cycle after rFSH in clomiphene citrate resistant PCOS women has been calculated to be 71% in a Cochrane review (Figure 2).128 Recent randomized trials have reported higher ovulation rates from 85% and up to 97% in this group of women.59,103,127 with comparable clinical pregnancy rates per woman ranging from 17% to 20% after one cycle,59,103,126 and a cumulative clinical pregnancy rate per woman of 42%.128 A similar cumulative live birth rate of 43% was reported by a subsequent RCT.129


Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Gibreel A, Bhattacharya S - Biologics (2010)

Meta-analysis of randomized trials of hMG versus rFSH for the outcome of pregnancy rate per patient in women undergoing ovulation induction for subfertility associated with polycystic ovarian syndrome. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001;2(2):CD002121.128 Copyright © Cochrane Collaboration, reproduced with permission.Abbreviations: HMG, human menopausal gonadotropin; RFSH, recombinant follicle stimulating hormone.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2819896&req=5

f2-btt-4-005: Meta-analysis of randomized trials of hMG versus rFSH for the outcome of pregnancy rate per patient in women undergoing ovulation induction for subfertility associated with polycystic ovarian syndrome. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001;2(2):CD002121.128 Copyright © Cochrane Collaboration, reproduced with permission.Abbreviations: HMG, human menopausal gonadotropin; RFSH, recombinant follicle stimulating hormone.
Mentions: The first baby born after ovulation induction by follitropin in a clomiphene resistant PCOS patient was reported in 1992.122 Randomized trials comparing follitropin alpha to other gonadotropins preparation or other ovulatory medications, in infertile women with WHO type II anovulation, have reported a live birth rate of 17% to 20%.59,123,124 The rate of successful ovulation has been reported to be between 57% and 85%.33,125–127 The pooled ovulation rate per cycle after rFSH in clomiphene citrate resistant PCOS women has been calculated to be 71% in a Cochrane review (Figure 2).128 Recent randomized trials have reported higher ovulation rates from 85% and up to 97% in this group of women.59,103,127 with comparable clinical pregnancy rates per woman ranging from 17% to 20% after one cycle,59,103,126 and a cumulative clinical pregnancy rate per woman of 42%.128 A similar cumulative live birth rate of 43% was reported by a subsequent RCT.129

Bottom Line: Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism.Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy.However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine and Dentistry, University of Aberdeen;

ABSTRACT
Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.

No MeSH data available.


Related in: MedlinePlus